Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

Santoro, Armando; Mazza, Rita; Spina, Michele; Califano, Catello; Specchia, Giorgina; Carella, Angelo Michele; Consoli, Ugo; Palombi, Francesca; Musso, Maurizio; Pulsoni, Alessandro; Kovalchuk, Sofya; Bonfichi, Maurizio; Ricci, Francesca; Fabbri, Alberto; Liberati, Anna Marina; Rodari, Marcello; Giordano, Laura; Chimienti, Emanuela; Balzarotti, Monica; Sorasio, Roberto; Gallamini, Andrea; Ghiggi, Chiara; Ciammella, Patrizia; Ricardi, Umberto; Chauvie, Stéphane; Carlo‐Stella, Carmelo; Merli, Francesco

doi:10.1007/s00277-021-04604-x

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adults with HL, the ABVD scheme has been considered the de facto standard of care for several decades due to its effectiveness and excellent toxicity profile. 12 , 13 ABVD continues to be widely used in resource-limited settings owing to low costs, ease of delivery, and limited acute toxicity, allowing for safe delivery, even at centres with suboptimal supportive care. In a survey of paediatric oncology providers in India, ABVD was the first-line chemotherapy in 73% of paediatric oncologic centers.…”

Section: Discussionmentioning

confidence: 99%

Hodgkin Lymphoma in Children: A 16-Year Experience at the Children’s Welfare Teaching Hospital of Baghdad, Iraq.

Testi,

Al-Jadiry,

Moleti

et al. 2024

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Background. Childhood Hodgkin lymphoma (HL) is an eminently curable disease. Good outcomes can be achieved even in resource-limited settings and increasingly, the focus is on limiting long-term toxicity. Contemporary treatment incorporates a risk-stratified, response-adapted approach using multiagent chemotherapy with/without low-dose radiotherapy. Many developing countries continue to use ABVD-based regimens due to limited acute toxicity, cost, and ease of delivery. Objective. We herein report the outcomes of childhood HL diagnosed and treated in an Iraqi single-center over a 16 years period. Methods. Children ≤14 years with biopsy-proven HL were enrolled. Most patients received ABVD chemotherapy or COPP/ABV when Dacarbazine was unavailable. Radiotherapy was not available. Results. Three hundred-three children were consecutively newly diagnosed with HL; 284 were considered eligible for the retrospective analysis (treatment refusals 9; deaths before therapy 5; initially diagnosed of non-Hodgkin lymphoma 5). ABVD scheme was administered to 184 children (65%), COPP/ABV to 83 (29%), other schemes to the remaining 17 patients. Complete response (CR) was achieved in 277 (98%); 4 (1.4%) showed disease progression and 1 stable disease. Four patients in CR abandoned therapy and were in CR at the time of analysis, 2 died from infection. Relapse occurred in 42 patients (15%). The 15-year OS and EFS are 89.7% and 70.3%, respectively. Conclusion. In this single-center, over a 16-year period, almost 90% of children suffering from HL survive, despite the numerous limitations in diagnostic procedures, shortage of chemotherapy, no radiotherapy facilities, absence of effective second-line treatments and finally therapy abandonment for social and financial reasons.

show abstract

Section: Discussionmentioning

confidence: 99%

Hodgkin Lymphoma in Children: A 16-Year Experience at the Children’s Welfare Teaching Hospital of Baghdad, Iraq.

Testi,

Al-Jadiry,

Moleti

et al. 2024

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Oncology is the discipline that published the most clinical studies in oncology cardiology, accounting for more For the co-authorship map, there is very little collaboration between the authors, and their relationships are scattered. Santoro, 27,28 Thomas Suter, [29][30][31][32][33] and Azarnia [34][35][36] are the top three most productive authors. They are both experts in the field of oncology and have conducted multiple studies and published many high-quality articles in their respective areas of expertise.…”

Section: Generation Informationmentioning

confidence: 99%

Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

Lini,

Rong,

Wei

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background We aim to establish the characteristics of published cardio‐oncology research of clinical trials by bibliometric analysis and to talk about the prospects and difficulties facing the development of cardio‐oncology. Methods Search of data related to clinical trials in cardiac oncology from 1990 to 2022 from the Web of Science core collection. Using CiteSpace to perform co‐citation analysis of authors, countries (regions) and institutions, journals and cited journals, cited authors and cited literature, and keywords. Results Of the 607 clinical trial studies, the number of papers published per year has increased over time. The regions with the greatest influence were North America (especially the United States) and Europe. Multicenter research has always been the focus of cardio‐oncology research, but cross‐regional cooperation was still lacking. Myocardial toxicity caused by anthracyclines has received the earliest attention and has been studied for the longest time. Meanwhile, the efficacy and cardiotoxicity of new anticancer drugs always came into focus, but at a slow pace. Few studies on myocardial toxicity were related to the treatment of tumors except breast cancer. Risk factors, heart disease, adverse outcomes, follow‐up, and intervention protection were the major hotspots revealed by co‐citation cluster. Conclusions There is great potential for the development of clinical trials in cardio‐oncology, especially in multicenter cooperation across different regions. Expansion of tumor types, myocardial toxicity of different drugs, and effective interventions in the research direction and design of clinical trials are necessary.

show abstract

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

Cited by 2 publications

References 26 publications

Hodgkin Lymphoma in Children: A 16-Year Experience at the Children’s Welfare Teaching Hospital of Baghdad, Iraq.

Hodgkin Lymphoma in Children: A 16-Year Experience at the Children’s Welfare Teaching Hospital of Baghdad, Iraq.

Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis

Contact Info

Product

Resources

About